The AAPS Journal

, Volume 7, Issue 3, pp E566–E571 | Cite as

Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs

  • Valeria Alcon
  • Maria Baca-Estrada
  • Marco Vega-Lopez
  • Philip Willson
  • Lorne A. Babiuk
  • Praveen Kumar
  • Rolf Hecker
  • Marianna Foldvari


The ineffectiveness of simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies of strategies for appropriate delivery systems and adjuvants. Biphasic lipid vesicles are formulations suitable for the delivery of proteins, peptides, and oligo/polynucleotides. The purpose of these studies was to investigate the ability of biphasic lipid vesicles (as vaccinetargeting adjuvants) containing a bacterial antigen and unmethylated oligonucleotides containing CGdinucleotides-CpG motifs (CpG ODNs) to induce systemic and mucosal immune responses in pigs. Results showed that while the protein, either alone or with CpG ODNs, did not induce mucosal immune responses, administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in induction of boty systemic and local antibody responses after immunization using a combined mucosal/systemic approach.


Mucosal immunity biphasic lipid delivery systems CpG ODNs porcine Actinobacillus pleuropneumoniae 


  1. 1.
    Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modofied vaccinia virus Ankara.J Immunol. 2003;171:1602–1609.PubMedGoogle Scholar
  2. 2.
    Kaul D, Ogra PL. Mucosal resonses to parenteral and mucosal vaccines.Dev Biol Stand. 1998;95:141–146.PubMedGoogle Scholar
  3. 3.
    Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.Virology. 1998;252:39–45.PubMedCrossRefGoogle Scholar
  4. 4.
    McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.FEMS Immunol Med Microbiol. 2002;32:179–185.PubMedCrossRefGoogle Scholar
  5. 5.
    McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development.Vaccine. 1992;10:75–88.PubMedCrossRefGoogle Scholar
  6. 6.
    Liljeqvist S, Stahl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines.J Biotechnol. 1999;73:1–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.Immunol Today. 1999;20:493–500.PubMedCrossRefGoogle Scholar
  8. 8.
    Takahashi I, Marinaro M, Kiyono H, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.J Infect Dis. 1996;173:627–635.PubMedGoogle Scholar
  9. 9.
    Williams NA, Hirst TR, Nashar TO. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.Immunol Today. 1999;20:95–101.PubMedCrossRefGoogle Scholar
  10. 10.
    van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.J Immunol. 2000;165:4778–4782.PubMedGoogle Scholar
  11. 11.
    Krieg AM. Immune effects and mechanisms of action of CpG motifs.Vaccine. 2000;19:618–622.PubMedCrossRefGoogle Scholar
  12. 12.
    McCluskie MJ, Davis HL. CpG DNA as mucosal adjuvant.Vaccine. 1999;18:231–237.PubMedCrossRefGoogle Scholar
  13. 13.
    Babiuk S, Baca-Estrada ME, Middleton DM, Hecker R, Babiuk LA, Foldvari M. Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration.Curr Drug Deliv. 2004;1:9–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Alcon VL, Foldvari M, Snider M, et al. Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery systems (Biphasix).Vaccine. 2003;21:1811–1814.PubMedCrossRefGoogle Scholar
  15. 15.
    Gerlach GF, Anderson C, Klashinsky S, Rossi-Campos A, Potter AA, Willson PJ. Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1.Infect Immun. 1993;61:565–572.PubMedGoogle Scholar
  16. 16.
    Foldvari M, inventor. US patent 5 853 755. December 29, 1998.Google Scholar
  17. 17.
    Foldvari M, Baca-Estrada ME, inventor. US patent 5 993 852. November 30, 1999.Google Scholar
  18. 18.
    Rankin R, Pontarollo R, Ioannou X, et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved.Antisense Nucleic Acid Drug Dev. 2001;11:333–340.PubMedCrossRefGoogle Scholar
  19. 19.
    Foss DL, Murtaugh MP. Mucosal immunogenicity and adjuvanticity of cholera toxin in swine.Vaccine. 1999;17: 788–801.PubMedCrossRefGoogle Scholar
  20. 20.
    Capozzo AV, Cuberos L, Levine MM, Pasetti MF. Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers.Infect Immun. 2004;72:4637–4646.PubMedCrossRefGoogle Scholar
  21. 21.
    Gockel CM, Bao S, Beagley KW. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract.Mol Immunol. 2000;37:537–544.PubMedCrossRefGoogle Scholar
  22. 22.
    Snider DP. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins.Crit Rev Immunol. 1995;15:317–348.PubMedGoogle Scholar
  23. 23.
    Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.J Immunol. 1998;161:3211–3214.PubMedGoogle Scholar
  24. 24.
    Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.J Immunol. 2001;166:3451–3457.PubMedGoogle Scholar
  25. 25.
    McCluskie MJ, Weeratna RD, Davis HL. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.Mol Med. 2000;6:867–877.PubMedGoogle Scholar
  26. 26.
    McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.Vaccine. 2001;19:2657–2660.PubMedCrossRefGoogle Scholar
  27. 27.
    Olszewska W, Partidos CD, Steward MW. Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants.Infect Immun. 2000;68:4923–4929.PubMedCrossRefGoogle Scholar
  28. 28.
    Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix).J Pharm Pharmacol. 2002;54:1609–1614.PubMedCrossRefGoogle Scholar
  29. 29.
    Farman CA, Kornbrust DJ. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications.Toxicol Pathol. 2003;31:119–122.PubMedGoogle Scholar
  30. 30.
    Klimuk SK, Semple SC, Nahimey PN, et al. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity.J Pharmacol Exp Ther. 2000;292:480–488.PubMedGoogle Scholar
  31. 31.
    De Oliveira MC, Boutet V, Fattal E, et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice.Life Sci. 2000;67:1625–1637.PubMedCrossRefGoogle Scholar
  32. 32.
    Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.Infect Immun. 1982;36:1102–1108.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2005

Authors and Affiliations

  • Valeria Alcon
    • 1
    • 2
  • Maria Baca-Estrada
    • 2
  • Marco Vega-Lopez
    • 2
  • Philip Willson
    • 2
  • Lorne A. Babiuk
    • 2
  • Praveen Kumar
    • 3
  • Rolf Hecker
    • 4
  • Marianna Foldvari
    • 1
  1. 1.Department of Pharmaceutics/Pharmacy, College of Pharmacy and NutritionUniversity of SaskatchewanSaskatoonCanada
  2. 2.Vaccine and Infectious Disease OrganizationSaskatoonCanada
  3. 3.PharmaDerm Laboratories LtdSaskatoonCanada
  4. 4.QIAGEN GmbHHildenGermany

Personalised recommendations